BRCA1 and Familial prostate cancer: Originally, this concept of synthetic lethality implies a treatment by PARP-inhibition alone, as it is already successfully applied to breast, ovarian and prostate cancer patients defective in HR due to mutations in BRCA1/2 [42, 45].